|1.||Melani, Alessia: 4 articles (08/2015 - 01/2003)|
|2.||Pedata, Felicita: 4 articles (08/2015 - 01/2003)|
|3.||Monopoli, Angela: 4 articles (07/2008 - 01/2003)|
|4.||Wardas, Jadwiga: 3 articles (12/2009 - 03/2003)|
|5.||Morelli, Micaela: 3 articles (12/2009 - 09/2004)|
|6.||Greenlee, William J: 3 articles (07/2008 - 03/2007)|
|7.||Ng, Kwokei: 3 articles (07/2008 - 03/2007)|
|8.||Neustadt, Bernard R: 3 articles (07/2008 - 03/2007)|
|9.||Ongini, Ennio: 3 articles (03/2007 - 08/2003)|
|10.||Corti, Francesca: 2 articles (08/2015 - 01/2011)|
10/01/2013 - "SCH 58261 also suppressed ischemia-induced protein nitration and oxidation. "
01/10/2003 - "The selective A2A receptor antagonist SCH 58261 reduces striatal transmitter outflow, turning behavior and ischemic brain damage induced by permanent focal ischemia in the rat."
01/10/2003 - "In this study we verified if the protective effect of the selective A(2A) antagonist, SCH 58261, could be attributed to the reduction of the excitatory amino acid outflow induced by cerebral focal ischemia. "
02/16/2006 - "These results indicate that the protective effect of the adenosine antagonist SCH 58261 during ischemia is not due to reduced microglial activation but involves inhibition of phospho-p38 MAPK and suggest that treatment with the A2A antagonist from the first hour to several hours after ischemia may be a useful therapeutic approach in cerebral ischemia."
10/01/2013 - "SCH 58261 selectively inhibited the ischemia-induced phosphorylation of NR1, Na(+),K(+)-ATPase, and cAMP-regulated phosphoprotein 32 KDa (DARPP32) at PKA-sensitive sites at 3 hours of recovery and improved Na(+),K(+)-ATPase activity. "
|2.||Middle Cerebral Artery Infarction (Middle Cerebral Artery Syndrome)
02/01/2002 - "Our study was aimed to investigate the effect of the blockade of A(2A)receptors, by Sch 58261, on the expression of the early gene c-fos, in a model of permanent middle cerebral artery occlusion (pMCAo), in rats. "
02/16/2006 - "We investigated the protective effect of subchronic treatment of the A2A receptor antagonist, SCH 58261 (0.01 mg/kg, i.p.), administered 5 min, 6 h and 15 h after permanent right middle cerebral artery occlusion (MCAo). "
08/01/2015 - "In previous studies, in the model of permanent middle cerebral artery occlusion (pMCAo), the adenosine A2A receptor antagonist, SCH58261, administered soon after ischemia, proved protective against excessive glutamate outflow in the first 4 h after ischemia and against neurological deficit and tissue damage evaluated 24 h after pMCAo. "
|3.||Huntington Disease (Huntington's Disease)
01/25/2007 - "These findings extend to the behavioural parameters the protective effects of SCH 58261 in the QA model of Huntington's disease."
01/25/2007 - "In this study, we assessed the neuroprotective effects of the adenosine A(2A) receptor antagonist SCH 58261 on the progressive behavioural alterations reported in the QA rat model of Huntington's disease. "
11/01/2007 - "The effect of chronic treatment with the selective adenosine A2A receptor antagonist SCH 58261 on the behavioral and electrophysiological alterations typical of R6/2 mice (a transgenic mouse model of Huntington's disease, HD), has been studied. "
11/01/2007 - "Behavioral and electrophysiological effects of the adenosine A2A receptor antagonist SCH 58261 in R6/2 Huntington's disease mice."
03/01/2002 - "The aim of the present study was to evaluate whether, and by means of which mechanisms, the adenosine A2A receptor antagonist SCH 58261 [5-amino-7-(2-phenylethyl)-2-(2-furyl)-pyrazolo[4,3-e]-1,2,4-triazolo[1,5-c]pyrimidine] exerted neuroprotective effects in a rat model of Huntington's disease. "
09/01/2004 - "In the present study, the number of tremor episodes and jaw movements were evaluated to assess the effects of the selective A2A antagonists SCH 58261 and SCH BT2 on tremorgenesis. "
09/01/2004 - "SCH 58261 dose-dependently, and maximally at 5 mg/kg, reduced the number of both tremor episodes (-35%) and jaw movements (-50%), induced in rats by tacrine (2.5 mg/kg ip). "
09/01/2004 - "Infusion of SCH BT2 (5 microg/microl), a water-soluble analogue of SCH 58261, in VLS antagonized both tremor episodes (-68%) and jaw movements (-76%) elicited by tacrine (2.5 mg/kg ip), whereas SCH BT2 infusion in DMS was less effective in blocking jaw movements (-50%) and did not significantly affect the number of tremor episodes. "
10/25/2006 - "Moreover, the ineffectiveness of SCH 58261 in blocking pilocarpine-stimulated perioral tremor suggests that the antitremorigenic effects of A(2A) antagonists described here are not related to a direct action on muscarinic receptor. "
10/25/2006 - "Systemic administration of the A(2A) antagonist SCH 58261 dose-dependently reduced the magnitude of perioral tremor induced by the acetylcholinesterase inhibitor tacrine (2.5 mg/kg). "
05/01/2009 - "Treatment with the selective A1 antagonist CPT also produced a significant reduction in catalepsy, as did treatment with the selective A2A antagonist SCH58261. "
03/01/2007 - "Employing the known pyrazolo[4,3-e]-1,2,4-triazolo[1,5-c]pyrimidine A2A antagonist SCH 58261 as a starting point, we identified the potent and selective (vs. A1) antagonist 11h, orally active in the rat haloperidol-induced catalepsy model. "
07/11/2003 - "Systemic administration of SCH 58261 (5 mg/kg i.p., 3 times, every 3 h, 10 min before haloperidol), partially decreased the haloperidol-induced catalepsy and the increase in the PENK mRNA expression in both dorsolateral and ventrolateral parts of the striatum at all three examined levels. "
07/11/2003 - "Since it is believed that main motor symptoms of PD are due to the overactivity of the GABAergic striopallidal pathway, the aim of the present study was to find out whether SCH 58261, a selective antagonist of the adenosine A(2A) receptors, is capable of counteracting both the catalepsy and the enhancement of proenkephalin (PENK) mRNA expression in the rat striatum, induced by haloperidol administered at 1.5 mg/kg s.c. "
|1.||Adenosine A2A Receptor (Adenosine A2A Receptors)
|2.||Glutamic Acid (Glutamate)
|3.||2- furan- 2- yl- 7- 3- (4- (4- (4- methylpiperazine- 1- sulfonyl)phenylethyl)- 7H- pyrazolo(4,3- e)(1,2,4)triazolo- (1,5- c)pyrimdin- 5- ylamine)
|4.||D-Aspartic Acid (D Aspartate)
|6.||2- (4- (2- carboxyethyl)phenethylamino)- 5'- N- ethylcarboxamidoadenosine
|7.||Protein Kinases (Protein Kinase)
|8.||Adenosine Triphosphatases (ATPase)